103 related articles for article (PubMed ID: 34968866)
1. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract][Full Text] [Related]
2. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Luo D; Digiovanni MG; Wei R; Lacomb JF; Williams JL; Rigas B; Mackenzie GG
Carcinogenesis; 2020 Jul; 41(7):927-939. PubMed ID: 31584613
[TBL] [Abstract][Full Text] [Related]
3. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.
Mattheolabakis G; Papayannis I; Yang J; Vaeth BM; Wang R; Bandovic J; Ouyang N; Rigas B; Mackenzie GG
Cancer Prev Res (Phila); 2016 Jul; 9(7):624-34. PubMed ID: 27138793
[TBL] [Abstract][Full Text] [Related]
4. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.
Goetze RG; Buchholz SM; Ou N; Zhang Q; Patil S; Schirmer M; Singh SK; Ellenrieder V; Hessmann E; Lu QB; Neesse A
Cells; 2019 Jun; 8(6):. PubMed ID: 31181844
[No Abstract] [Full Text] [Related]
8. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
Huang L; Wong CC; Mackenzie GG; Sun Y; Cheng KW; Vrankova K; Alston N; Ouyang N; Rigas B
BMC Cancer; 2014 Feb; 14():141. PubMed ID: 24575839
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Husain K; Centeno BA; Chen DT; Hingorani SR; Sebti SM; Malafa MP
Cancer Prev Res (Phila); 2013 Oct; 6(10):1074-83. PubMed ID: 23963802
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
[TBL] [Abstract][Full Text] [Related]
11. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Kaushik G; Seshacharyulu P; Rauth S; Nallasamy P; Rachagani S; Nimmakayala RK; Vengoji R; Mallya K; Chirravuri-Venkata R; Singh AB; Foster JM; Ly QP; Smith LM; Lele SM; Malafa MP; Jain M; Ponnusamy MP; Batra SK
Oncogene; 2021 Jan; 40(4):848-862. PubMed ID: 33288882
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
15. Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Luo D; Fraga-Lauhirat M; Millings J; Ho C; Villarreal EM; Fletchinger TC; Bonfiglio JV; Mata L; Nemesure MD; Bartels LE; Wang R; Rigas B; Mackenzie GG
Carcinogenesis; 2019 Dec; 40(12):1480-1491. PubMed ID: 30994173
[TBL] [Abstract][Full Text] [Related]
16. Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
Torres MP; Rachagani S; Souchek JJ; Mallya K; Johansson SL; Batra SK
PLoS One; 2013; 8(11):e80580. PubMed ID: 24278292
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras
Hu S; Pan L; Shangguan J; Figini M; Eresen A; Sun C; Wang B; Ma Q; Hu C; Yaghmai V; Velichko Y; Yang J; Zhang Z
J Immunol Methods; 2019 Feb; 465():1-6. PubMed ID: 30468734
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
19. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
20. A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.
Cortez NE; Rodriguez Lanzi C; Hong BV; Xu J; Wang F; Chen S; Ramsey JJ; Pontifex MG; Müller M; Vauzour D; Vahmani P; Hwang CI; Matsukuma K; Mackenzie GG
Cancer Res Commun; 2022 Sep; 2(9):951-965. PubMed ID: 36382086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
